Atopic dermatitis clinical and non-clinical studies, key players, treatment evaluation, emerging therapies, treatment algorithms, pipeline analysis | Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
The atopic dermatitis (AD) space includes several key players, including Teres Bio, Qurient Co., Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd., GI Innovation, AnaptysBio, MC2 Therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, and TWi Biotechnology.
According to DelveInsight, the atopic dermatitis pipeline consists of over 100 leading companies actively developing over 110 therapeutics targeted at the treatment of AD.
Overview of atopic dermatitis:
Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin disease that often begins in early childhood but can occur at any age. Its main characteristics are: Itching, redness, rashAnd it is often affected by Genetic predisposition, overactive immune system, infection, allergies, or environmental irritantsModerate to severe cases of Alzheimer's disease often include the following symptoms: Asthma, hay fever, food allergies, which is the most prevalent chronic skin disease among children.
The mechanism of Alzheimer's disease is multifactorial, involving skin barrier dysfunction, immune dysregulation, and environmental factors. Mutation of the Filaggrin gene aggravates the condition by causing Increased transepidermal water loss, changes in skin pH, dehydration, and impairing the skin's barrier function.Th2 and Th1 cytokines Drive Immune dysfunction and allergic reactionsCharacteristic histological features include:Cavernous, promoting the infiltration of inflammatory cells. Dendritic Cell Subtypes, including Langerhans cells and inflammatory dendritic epidermal cells, play an important role in the development of the disease.
Request the full Atopic Dermatitis Pipeline Insights report:
https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=hpr
About the Report – “Atopic Dermatitis Pipeline Insights 2024”
DelveInsight's "Atopic Dermatitis Pipeline Insights 2024" report provides an extensive overview of ongoing clinical development activity and market opportunities in the atopic dermatitis therapeutic field.
Key highlights from the pipeline report:
-
The report profile is Robust Development Pipeline, and over 100 active companies Pursue Over 110 treatments for atopic dermatitis.
-
Leading AD drug developers include: Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, and SHROFF Innovation for Science。
-
Other notable players: Teres Bio, Qurient Co., Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd., GI Innovation, AnaptysBio, MC2 Therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, および English Biotechnology.
-
Promising drug candidates currently in development include: Tapinarof, etrasimod, B244, lirentelimab, and QY201。
Recent advances in the AD pipeline segment:
-
January 2025Gilead Sciences has entered into a collaboration withLeo Pharma(Denmark) will collaborate on developing treatments for inflammatory skin diseases, including Alzheimer's disease. Oral STAT6 Program, a promising pathway for AD.
-
December 2024: of FDA approves Galderma's nemolizumab is indicated for moderate to severe Alzheimer's disease in patients aged 12 years and older who have had an inadequate response to topical treatments.Interleukin-31 (IL-31) Receptor combats itching and inflammation.
-
December 2024: FDA-approved Vtama Cream is used to treat AD in adults and children aged 2 years and older. Nonsteroidal topical treatmentsPhase 3 clinical trials have shown a significant reduction in itch and significant skin clearance.
-
September 2024: OrgansAnnouncement of acquisition plansDermavantDermavant is expanding its presence in dermatology. V Tama Cream was originally approved for psoriasis in 2022 but is under FDA review for AD and is expected to be approved by the end of the year.
-
September 2024: of FDA approves Eli Lilly's injectable treatment Evgris for moderate to severe eczema in patients 12 years and older. This monthly injection provides targeted neutralizationIL-13, a key cytokine in AD progression.
Pipeline Analysis and Therapeutic Evaluation:
DelveInsight reports provide:
-
Key Company Insights: In the development of drugs to treat Alzheimer's disease
-
Evaluation of therapeutic candidatesClinical Stage(Early, mid, late)
-
Analysis of Active and Inactive(Discontinued/Inactive) Pipeline Projects
-
Overview Emerging Drugs Classified by Stage of disease, route of administration, target receptor, monotherapy/combination therapy, Mechanism of action, and Molecular Type
-
Comprehensive coverageCollaboration and licensing agreements, and Financial activities
👉 Download a free sample page of the report:
https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=hpr
New drugs in the Alzheimer's disease pipeline:
-
Tapinaroff – Dermavant Sciences
-
Etrasimod – Pfizer
-
B244 – AOB Biomes
-
Lirentelimab – Alacos Co., Ltd.
-
Q3 201 – E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Key Players in Atopic Dermatitis Development:
More Top 100 Large Enterprises. We are investing in the development of treatments for Alzheimer's disease. Dermavant Sciences There are candidates in Phase III, currently in the most advanced stage of development.
The report includes: Over 110 productsAcross the different stages of development:
-
Late stage (Phase III)
-
Mid-term (Phase II)
-
Early Stage (Phase I)
-
Preclinical and discovery stages
-
Inactive or discontinued Project
Therapeutic evaluation by route of administration:
Drugs in the AD pipeline are classified based on route of administration.
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Treatment evaluation by molecular type:
Pipeline candidates include:
-
Monoclonal antibodies
-
Low molecular weight
-
peptide
Download the sample report to explore new therapeutics, pipeline insights, and company strategies in AD development.:
table of contents
1. Introduction to the report
2. Executive Summary
3. Current treatment patterns for atopic dermatitis
4. Atopic Dermatitis – DelveInsight Analytical Perspective
5. Treatment evaluation
6. Atopic dermatitis late-stage products (Phase III)
7. Mid-stage products for atopic dermatitis (Phase II)
8. Early Stage Products (Phase I)
9. Preclinical and discovery stage products
10. Inactive Products
11. Dormant products
12. Atopic dermatitis discontinued products
13. Atopic Dermatitis Product Profile
14. Major Companies in Atopic Dermatitis
15. Main products for atopic dermatitis
16. Inactive and Discontinued Products
17. Unmet needs of atopic dermatitis
18. Future outlook for atopic dermatitis
19. Review by Atopic Dermatitis Analyst
20. Appendix
21. Reporting Methods
Contact Information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading business consultancy and market research firm focused on life sciences, supporting pharmaceutical companies by providing comprehensive end-to-end solutions to improve their business performance.
English
Arabic
Français
Español
Português
Deutsch
Dutch
Italiano
Russian
Romaian